KRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
KORU Medical Systems, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.02+0.02 (+0.67%)
Close on Oct 19, 2026
- Market cap
- $149.52M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2025
Gross margin
62.3%+0.5 pts over 5 years
Operating margin
-7.2%−2.0 pts over 5 years
Net margin
-6.4%−1.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +22.2% | +13.8% | +11.2% | +13.8% | |
| Gross profit | +20.0% | +18.5% | +11.4% | +14.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 13.1% | -5.1% | -15.6% | |
| Return on assets | 11.2% | -4.5% | -9.5% | |
| Current ratio | 8.54 | 10.24 | 2.44 | |
| Interest coverage | 2241.0× | – | – | |
| Inventory turnover | 4.5× | 2.0× | 4.8× | |
| Capex to revenue | 5.3% | 3.8% | 2.3% | |
| Diluted shares | 38M | 42M | 46M |
Where the cash went
Fiscal 2021 to 2025, five years combined
KORU Medical Systems generated $15.40M from operations and spent $6.12M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$15.40M
Used
$6.12M
Capital expenditure$6.12M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-6.4%
×Asset turnover1.48×
×Equity multiplier1.64×
=Return on equity, FY2025-15.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -6.4% | 1.48× | 1.64× | -15.6% |
| FY2024 | -18.0% | 1.21× | 1.50× | -32.6% |
| FY2023 | -48.2% | 0.81× | 1.37× | -53.2% |
| FY2022 | -31.0% | 0.67× | 1.23× | -25.5% |
| FY2021 | -19.4% | 0.58× | 1.12× | -12.6% |
| FY2020 | -5.0% | 0.90× | 1.14× | -5.1% |
| FY2017 | -4.4% | 1.48× | 1.20× | -7.8% |
| FY2016 | 6.4% | 1.56× | 1.17× | 11.7% |
| FY2015 | 6.7% | 1.67× | 1.18× | 13.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$2.64M
- Cash generatingOperating cash flow above zero$462.41K
- Return on assets improvedROA up on the prior year-21.3% → -9.7%
- Earnings backed by cashOperating cash flow above net income$462.41K vs -$2.64M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.66 → 2.44
- No dilutionShare count did not rise46M → 46M
- Gross margin improvedGross margin up on the prior year63.40% → 62.26%
- More efficientAsset turnover rose1.18 → 1.51